Manjandavida, FPStathopoulos, CZhang, JHonavar, SGShields, CL2020-04-102020-04-102019-06Manjandavida FP, Stathopoulos C, Zhang J, Honavar SG, Shields CL. Intra-arterial chemotherapy in retinoblastoma – A paradigm change. Indian Journal of Ophthalmology. 2019 Jun; 67(6): 740-7540301-47381998-3689http://imsear.searo.who.int/handle/123456789/197323Intra-arterial chemotherapy (IAC), also known as superselective ophthalmic artery chemotherapy or chemosurgery, is currently widely accepted as one of the primary treatment modalities for intraocular retinoblastoma worldwide. Following the introduction of the technique in 1998, IAC has evolved over the past decades to be safer and more effective. Accumulated evidence shows that IAC is more effective in providing eye salvage in group D and E retinoblastoma as compared to conventional systemic intravenous chemotherapy (IVC). In contrast to IVC, IAC has the added benefits of reduced overall treatment duration and minimal systemic toxicity. This review provides a comprehensive update on the history, technique, indications, contraindications, and outcome of IAC. We have also identified the strengths, weaknesses, opportunities and threats (SWOT analysis) of the technique in this review.Retinoblastomaintra-arterial chemotherapyselective ophthalmic artery chemotherapysuperselective ophthalmic artery chemotherapychemosurgeryJournal ArticleIndiaOcular Oncology Service, HORUS Specialty Eye Care and Prabha Eye Clinic, Bangalore, India; Women's and Children's Hospital, Guangzhou, ChinaPediatric Ocular Oncology Service, Jules-Gonin Eye Hospital, Lausanne, SwitzerlandWomen's and Children's Hospital, Guangzhou, ChinaOcular Oncology Service, Center for Sight, Hyderabad, IndiaOcular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA